Geoff Ling, MD, PhD
Jean Ann Brock Distinguished Chair Co-Leader BrainHealth Project
Pharmacologist, physician and retired U.S. Army Colonel, Dr. Geoffrey Ling served as the founding director of the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA). A serial entrepreneur, he has successfully led strategic partnerships and investment strategies for several companies, leading concepts through FDA approval and commercialization to significantly enhance enterprise value.
At Center for BrainHealth, he guides the growth of The BrainHealth Project and continues to influence approaches and strategies to keep brain health "left of boom" for communities across the country.
"When I was in the military, we referred to ‘left of boom’ as staying ahead of a potentially catastrophic event. For the first time ever, we have a way to stay ‘left of boom’ when it comes to our brain’s health and fitness – and it’s backed by a body of science that is growing by leaps and bounds. Cognitive neuroscience is where some of the most exciting, transformative discoveries are happening today."
— Geoff Ling, MD, PhD
Left of boom is a military term to prevent and protect from explosions – making proactive decisions ahead of time. When it comes to brain health, most people don’t think about it until something goes wrong – boom! By strengthening the brain’s health and function NOW – getting “left of boom” – we are giving ourselves protection to mitigate, overcome or even avoid some of the tough challenges that may lie ahead.
Learn key insights on how to be a forward-thinker with Geoff Ling, MD, PhD, professor and physician with Johns Hopkins, a co-leader of The BrainHealth® Project, retired United States Army colonel, and former director of the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office.
Geoffrey Ling (CEO, Ling and Associates) led the US Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office. Since then, Dr. Ling has been taking transformative technologies to market. Here, he shares a story of technologies with the potential to fundamentally change the entire pharmaceutical industry—and how we can address public health challenges and disasters.